Skip to main content
Premium Trial:

Request an Annual Quote

Alan Fletcher, Charles Blitzer

Premium
PerkinElmer announced this week that Alan Fletcher has joined the company as vice president of business development for its Life and Analytical Sciences business.
 
In this role, Fletcher will be responsible for growing the biodiscovery business by developing strategic partnerships and alliances in life sciences research, and by introducing new technologies for the GPCR, kinase, and biomarker drug target classes.
 
Prior to PerkinElmer, Fletcher held multiple positions in the science and discovery systems business units at GE Healthcare.
 

 
Znomics announced this week that Charles Blitzer has been named to its board of directors.
 
Prior to Znomics, Blitzer held a number of positions at Barbeau Pharma, Fulcrum Pharma, and MGI Pharma.
 
From 1989 to 1992, Blitzer was with Marion Merrill Dow, last serving as vice president of corporate development. At Marion Laboratories, from 1977 to 1989, he was vice president of licensing and business development; director of licensing; and general and patent counsel.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.